Причины и лечение гиперпигментации лица

Список использованной литературы:

1. U.S. Census Bureau. An Older and More Diverse Nation by Midcentury, 2008. Available at: http://www.census.gov/newsroom/releases/ archives/population/cb08-123.html (last accessed 25 June 2013).
2. Sharma VK, Sahni K, Wadhwani AR. Photodermatoses in pigmented skin. Photochem Photobiol Sci 2013; 12:65-77.
3. Taylor SC. Skin of color: biology, structure, function, and implications for dermatologic disease. J Am Acad Dermatol 2002; 46(2 Suppl.):S41-62.
4. Seiji M, Fitzpatrick TB, Simpson RT, Birbeck MS. Chemical composition and terminology of specialized organelles (melanosomes and melanin granules) in mammalian melanocytes. Nature 1963; 197:1082.
5. Iozumi K, Hoganson GE, Pennella R et al. Role of tyrosinase as the determinant of pigmentation in cultured human melanocytes. J Invest Dermatol 1993; 100:806-1 1.
6. Wakamatsu K, Kavanagh R, Kadekaro AL et al. Diversity of pigmentation in cultured human melanocytes is due to differences in the type as well as quantity of melanin. Pigment Cell Res 2006; 19:154-62.
7. Chedekel MR, Smith SK, Post PW et al. Photodestruction of pheomelanin: role of oxygen. Proc Natl Acad Sci USA 1978; 75:5395-9.
8. Sarna T, Menon IA, Sealy RC. Photoinduced oxygen consumption in melanin systems - II. Action spectra and quantum yields for pheomelanins. Photochem Photobiol 1984; 39:805-9.
9. Parra EJ. Human pigmentation variation: evolution, genetic basis, and implications for public health. Am J Phys Anthropol 2007; 134 (Suppl. 45):85-105.
10. Society for Experimental Biology. Mitochondria and Other Cytoplasmic Inclusions. New York: Academic Press, 1959.
11. Szabo G, Gerald AB, Pathak MA, Fitzpatrick TB. Racial differences in the fate of melanosomes in human epidermis. Nature 1969; 222:1081-2.
12. Staricco RJ, Pinkus H. Quantitative and qualitative data on the pigment cells of adult human epidermis. J Invest Dermatol 1957; 28:33-45.
13. Toda K, Pathak MA, Parrish JA et al. Alteration of racial differences in melanosome distribution in human epidermis after exposure to ultraviolet light. Nat New Biol 1972; 236:143-5.
14. Montagna W, Carlisle K. The architecture of black and white facial skin. J Am Acad Dermatol 1991; 24:929-37.
15. Ranu H, Thng S, Goh BK et al. Periorbital hyperpigmentation in Asians: an epidemiologic study and a proposed classification. Dermatol Surg 2011; 37:1297-303.
16. Kaidbey KH, Agin PP, Sayre RM, Kligman AM. Photoprotection by melanin - a comparison of black and Caucasian skin. J Am Acad Dermatol 1979; 1:249-60.
17. Masu S, Seiji M. Pigmentary incontinence in fixed drug eruptions. Histologic and electron microscopic findings. J Am Acad Dermatol 1983; 8:525-32.
18. Bolognia JL, Jorizzo JL, Schaffer JV et al., eds. Dermatology, 3rd edn. St Louis: Mosby, 2012.
19. Baumann L, Rodriguez D, Taylor SC, Wu J. Natural considerations for skin of color. Cutis 2006; 78(6 Suppl.):2-19.
20. Sarkar R. Idiopathic cutaneous hyperchromia at the orbital region or periorbital hyperpigmentation. J Cutan Aesthet Surg 2012; 5:183-4.
21. Roh MR, Chung KY. Infraorbital dark circles: definition, causes, and treatment options. Dermatol Surg 2009; 35:1163-71.
22. Malakar S, Lahiri K, Banerjee U et al. Periorbital melanosis is an extension of pigmentary demarcation line-F on face. Indian J Dermatol Venereol Leprol 2007; 73:323-5.
23. Verschoore M, Gupta S, Sharma VK, Ortonne JP. Determination of melanin and haemoglobin in the skin of idiopathic cutaneous hyperchromia of the orbital region (ICHOR): a study of Indian patients. J Cutan Aesthet Surg 2012; 5:176-82.
24. Watanabe S, Nakai K, Ohnishi T. Condition known as ‘dark rings under the eyes’ in the Japanese population is a kind of dermal melanocytosis which can be successfully treated by Q-switched ruby laser. Dermatol Surg 2006; 32:785-9; discussion 789.
25. Khanna N, Rasool S. Facial melanoses: Indian perspective. Indian J Dermatol Venereol Leprol 2011; 77:552-63; quiz 564.
26. Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol 2011; 65:689-97; quiz 698.
27. Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001; 2:213-17.
28. Levitt J. The safety of hydroquinone: a dermatologist’s response to the 2006 Federal Register. J Am Acad Dermatol 2007; 57:85472.
29. Zawar VP, Mhaskar ST. Exogenous ochronosis following hydroquinone for melasma. J Cosmet Dermatol 2004; 3:234-6.
30. Charlin R, Barcaui CB, Kac BK et al. Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of der- moscopy. Int J Dermatol 2008; 47:19-23.
31. Adigun CG, Pandya AG. Improvement of idiopathic acanthosis nigricans with a triple combination depigmenting cream. J Eur Acad Dermatol Venereol 2009; 23:486-7.
32. Sinha S, Schwartz RA. Juvenile acanthosis nigricans. J Am Acad Dermatol 2007; 57:502-8.
33. Chan HH, Leung RS, Ying SY et al. A retrospective analysis of complications in the treatment of nevus of Ota with the Q-switched alexandrite and Q-switched Nd:YAG lasers. Dermatol Surg 2000; 26:1000-6.
34. Chan HH, Ying SY, Ho WS et al. An in vivo trial comparing the clinical efficacy and complications of Q-switched 755 nm alexandrite and Q-switched 1064 nm Nd:YAG lasers in the treatment of nevus of Ota. Dermatol Surg 2000; 26:919-22.
35. Hori Y, Kawashima M, Oohara K, Kukita A. Acquired, bilateral nevus of Ota-like macules. J Am Acad Dermatol 1984; 10:961-4.
36. Ee HL, Goh CL, Khoo LS et al. Treatment of acquired bilateral nevus of ota-like macules (Hori’s nevus) with a combination of the 532 nm Q-Switched Nd:YAG laser followed by the 1,064 nm Q-switched Nd:YAG is more effective: prospective study. Dermatol Surg 2006; 32:34^0.
37. Cho SB, Park SJ, Kim MJ, Bu TS. Treatment of acquired bilateral nevus of Ota-like macules (Hori’s nevus) using 1064-nm Q- switched Nd:YAG laser with low fluence. Int J Dermatol 2009; 48:1308-12.
38. Bliss JM, Ford D, Swerdlow AJ et al. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer 1995; 62:36776.
39. Rhodes AR, Albert LS, Barnhill RL, Weinstock MA. Sun-induced freckles in children and young adults. A correlation of clinical and histopathologic features. Cancer 1991; 67:1990-2001.
40. Rhodes AR, Harrist TJ, Momtaz TK. The PUVA-induced pigmented macule: a lentiginous proliferation of large, sometimes cytologically atypical, melanocytes. J Am Acad Dermatol 1983; 9:4758.
41. Schwartz RA. Erythema dyschromicum perstans: the continuing enigma of Cinderella or ashy dermatosis. Int J Dermatol 2004; 43:230-2.
42. Kanwar AJ, Dogra S, Handa S et al. A study of 124 Indian patients with lichen planus pigmentosus. Clin Exp Dermatol 2003; 28:481-5.
43. Al-Mutairi N, El-Khalawany M. Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non-randomized, prospective study. J Eur Acad Dermatol Venereol 2010; 24:535-40.
44. Kim JE, Won CH, Chang S et al. Linear lichen planus pigmentosus of the forehead treated by neodymium:yttrium-aluminum-garnet laser and topical tacrolimus. J Dermatol 2012; 39:189-91.
45. Dammak A, Masmoudi A, Boudaya S et al. Childhood actinic lichen planus (6 cases). Arch Pediatr 2008; 15:111 -14 (in French).
46. Meads SB, Kunishige J, Ramos-Caro FA, Hassanein AM. Lichen planus actinicus. Cutis 2003; 72:377-81.
47. Ramirez P, Feito M, Sendagorta E et al. Childhood actinic lichen planus: successful treatment with antimalarials. Australas J Dermatol 2012; 53:e10-13.
48. Sardana K, Relhan V, Garg V, Khurana N. An observational analysis of erythromelanosis follicularis faciei et colli. Clin Exp Dermatol 2008; 33:333-6.
49. Inamadar AC, Palit A, Sampagavi VV et al. Cutaneous manifestations of chikungunya fever: observations made during a recent outbreak in south India. Int J Dermatol 2008; 47:154-9.
50. Perez-Bernal A, Munoz-Perez MA, Camacho F. Management of facial hyperpigmentation. Am J Clin Dermatol 2000; 1:261-8.
51. Rigopoulos D, Gregoriou S, Katsambas A. Hyperpigmentation and melasma. J Cosmet Dermatol 2007; 6:195-202.
52. Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol 2011; 65:699-714; quiz 715.
53. Pathak MA, Riley FC, Fitzpatrick TB. Melanogenesis in human skin following exposure to long-wave ultraviolet and visible light. J Invest Dermatol 1962; 39:435^3.
54. Mahmoud BH, Hexsel CL, Hamzavi IH, Lim HW. Effects of visible light on the skin. Photochem Photobiol 2008; 84:450-62.
55. Jimbow K, Obata H, Pathak MA, Fitzpatrick TB. Mechanism of depigmentation by hydroquinone. J Invest Dermatol 1974; 62:43 6-49.
56. Briganti S, Camera E, Picardo M. Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Res 2003; 16:101 - 10.
57. Draelos ZD. Cosmetic therapy. In: Comprehensive Dermatologic Drug Therapy (Wolverton SE, ed), 2nd edn. Philadelphia: Saunders, 2007; 761-74.
58. Ennes SBP, Paschoalick RC, Mota De Avelar Alchorne M. A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma. J Dermatolog Treat 2000; 11:173-9.
59. Amer M, Metwalli M. Topical hydroquinone in the treatment of some hyperpigmentary disorders. Int J Dermatol 1998; 37:449-50.
60. Westerhof W, Kooyers TJ. Hydroquinone and its analogues in dermatology - a potential health risk. J Cosmet Dermatol 2005; 4:55-9.
61. Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Venereol 2006; 20:781-7.
62. Balina LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 1991; 30:893-5.
63. Ortonne JP. Retinoid therapy of pigmentary disorders. Dermatol Ther 2006; 19:280-8.
64. Kimbrough-Green CK, Griffiths CE, Finkel LJ et al. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol 1994; 130:727-33.
65. Griffiths CE, Finkel LJ, Ditre CM et al. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol 1993; 129:415-21.
66. Dogra S, Kanwar AJ, Parsad D. Adapalene in the treatment of melasma: a preliminary report. J Dermatol 2002; 29:539-0.
67. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a doubleblind, randomized, vehicle-controlled study. Cutis 2006; 77:45-50.
68. Tanghetti E, Dhawan S, Green L et al. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol 2010; 9:549-58.
69. Leenutaphong V, Nettakul A, Rattanasuwon P. Topical isotretinoin for melasma in Thai patients: a vehicle-controlled clinical trial. J Med Assoc Thai (Chotmaihet Thangphaet) 1999; 82:868-75.
70. Fleischer AB, Schwartzel EH, Colby SI, Altman DJ. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies. J Am Acad Dermatol 2000; 42:459-67.
71. Jarratt M. Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis 2004; 74:319-22.
72. Keeling J, Cardona L, Benitez A et al. Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: a case series and review of the literature. Cutis 2008; 81:179- 83.
73. Colby SI, Schwartzel EH, Huber FJ et al. A promising new treatment for solar lentigines. J Drugs Dermatol 2003; 2:147-52.
74. Kim YJ, Uyama H. Tyrosinase inhibitors from natural and synthetic sources: structure, inhibition mechanism and perspective for the future. Cell Mol Life Sci 2005; 62:1707-23.
75. Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg 1999; 25:282- 4.
76. Garcia A, Fulton JE Jr. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg 1996; 22:443-7.
77. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther 2007; 20:308-13.
78. Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A doubleblind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol 2004; 43:604-7.
79. Hwang SW, Oh DJ, Lee D et al. Clinical efficacy of 25% L-ascorbic acid (C’ensil) in the treatment of melasma. J Cutan Med Surg 2009; 13:74-81.
80. Kobayashi S, Takehana M, Itoh S, Ogata E. Protective effect of magnesium-L-ascorbyl-2 phosphate against skin damage induced by UVB irradiation. Photochem Photobiol 1996; 64:224-8.
81. Kameyama K, Sakai C, Kondoh S et al. Inhibitory effect of magnesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. J Am Acad Dermatol 1996; 34:29-33.
82. Yokota T, Nishio H, Kubota Y, Mizoguchi M. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res 1998; 11:355-61.
83. Amer M, Metwalli M. Topical liquiritin improves melasma. Int J Dermatol 2000; 39:299-301.
84. Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol 2006; 54(5 Suppl. 2):S272-81.
85. Seiberg M, Paine C, Sharlow E et al. The protease-activated receptor 2 regulates pigmentation via keratinocyte-melanocyte interactions. Exp Cell Res 2000; 254:25-32.
86. Paine C, Sharlow E, Liebel F et al. An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway. J Invest Dermatol 2001; 116:587-95.
87. Hermanns JF, Petit L, Pierard-Franchimont C et al. Assessment of topical hypopigmenting agents on solar lentigines of Asian women. Dermatology 2002; 204:281-6.
88. Chawla S, deLong MA, Visscher MO et al. Mechanism of tyrosinase inhibition by deoxyArbutin and its second-generation derivatives. Br J Dermatol 2008; 159:1267-74.
89. Boissy RE, Visscher M, DeLong MA. DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp Dermatol 2005; 14:601-8.
90. Hamed SH, Sriwiriyanont P, deLong MA et al. Comparative efficacy and safety of deoxyarbutin, a new tyrosinase-inhibiting agent. J Cosmet Sci 2006; 57:291-308.
91. Greatens A, Hakozaki T, Koshoffer A et al. Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible. Exp Dermatol 2005; 14:498-508.
92. Hakozaki T, Minwalla L, Zhuang J et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melano- some transfer. Br J Dermatol 2002; 147:20-31.
93. Hakozaki T, Takiwaki H, Miyamoto K et al. Ultrasound enhanced skin-lightening effect of vitamin C and niacinamide. Skin Res Tech- nol 2006; 12:105-13.
94. Bissett DL, Farmer T, McPhail S et al. Genomic expression changes induced by topical N-acetyl glucosamine in skin equivalent cultures in vitro. J Cosmet Dermatol 2007; 6:232-8.
95. Kimball AB, Kaczvinsky JR, Li J et al. Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial. Br J Dermatol 2010; 162:435-1.
96. Usuki A, Ohashi A, Sato H et al. The inhibitory effect of glycolic acid and lactic acid on melanin synthesis in melanoma cells. Exp Dermatol 2003; 12(Suppl. 2):43-50.
97. Guevara IL, Pandya AG. Safety and efficacy of 4% hydroqui- none combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J Dermatol 2003; 42:966-72.
98. Mauricio T, Karmon Y, Khaiat A. A randomized and placebo-controlled study to compare the skin-lightening efficacy and safety of lignin peroxidase cream vs. 2% hydroquinone cream. J Cosmet Dermatol 2011; 10:253-9.
99. Jimbow K. N-acetyl-4-S-cysteaminylphenol as a new type of de- pigmenting agent for the melanoderma of patients with melasma. Arch Dermatol 1991; 127:1528-34.
100. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975; 111:40-8.
101. Lynde CB, Kraft JN, Lynde CW. Topical treatments for melasma and postinflammatory hyperpigmentation. Skin Therapy Lett 2006; 11:1-6.
102. Torok HM, Jones T, Rich P et al. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12- month treatment for melasma. Cutis 2005; 75:57-62.
103. Ferreira Cestari T, Hassun K, Sittart A, de Lourdes Viegas M. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol 2007; 6:3 6-9.
104. Guevara IL, Pandya AG. Melasma treated with hydroquinone, tretinoin, and a fluorinated steroid. Int J Dermatol 2001; 40:21215.
105. Cestari T, Adjadj L, Hux M et al. Cost-effectiveness of a fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma. J Drugs Dermatol 2007; 6:153-60.
106. Kunachak S, Leelaudomlipi P, Wongwaisayawan S. Dermabrasion: a curative treatment for melasma. Aesthetic Plast Surg 2001; 25:114-17.